Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence

AstraZeneca1,077 enrolled

Overview

The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.

Study Type

OBSERVATIONAL

Enrollment

1,077

Conditions

Breast Cancer

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Early breast cancer * Post menopausal * Adjuvant hormonal Arimidex therapy

Locations (25)

Research Site

Balatonföldvár, Hungary

Research Site

Békéscsaba, Hungary

Outcomes

Primary Outcomes

Percent of patients remaining adherent to therapy with Arimidex

Time frame: Every 3 months

Secondary Outcomes

Questionnaire for factors influencing adherence

Time frame: Every 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.